Polycythemia

Educational clinical summary of Polycythemia for doctors and students: definition, workup, management, and key caveats. Not a substitute for guidelines.

Maintained by Dr. Vivek Karn Review process: editorial policy

Disclaimer: This information is for educational purposes only and should not be considered medical advice. It is intended for healthcare professionals as a comprehensive clinical reference. Clinical decisions must always be made by a qualified healthcare provider based on the patient's specific circumstances, considering the latest evidence and clinical judgment.

Overview

Definition: Polycythemia refers to an abnormal increase in the red blood cell (RBC) mass, typically indicated by an elevated hemoglobin (Hb) concentration, hematocrit (Hct), and/or RBC count. It can be absolute (increased RBC mass) or relative (decreased plasma volume). Polycythemia Vera (PV) is a specific myeloproliferative neoplasm (MPN) characterized by clonal hematopoietic stem cell proliferation leading primarily to erythrocytosis, often accompanied by leukocytosis, thrombocytosis, and splenomegaly.
Epidemiology:
- Incidence: The incidence of polycythemia vera is estimated to be 0.5-2.6 per 100,000 person-years, varying by geographic region and ethnicity.
- Prevalence: Approximately 22 per 100,000 population.
- Age: Primarily a disease of older adults, with a median age at diagnosis between 60 and 70 years. It is rare in individuals under 40.
- Gender: Slightly more common in men than women.
- Secondary polycythemia is far more common than PV, with prevalence depending on the underlying cause (e.g., chronic lung disease, sleep apnea, smoking).
Classification:
- Absolute Polycythemia: True increase in red cell mass.
  - Primary Polycythemia: Red cell production is independent of erythropoietin (EPO), due to an intrinsic defect in hematopoietic stem cells.
    - Polycythemia Vera (PV): The most common form of primary polycythemia, characterized by a clonal stem cell disorder, typically involving a JAK2 mutation (V617F or exon 12). EPO levels are usually low or undetectable.
    - Primary Familial and Congenital Polycythemia (PFCP): Rare, inherited forms, often due to EPO receptor mutations or other genetic defects leading to enhanced EPO signaling.
  - Secondary Polycythemia: Red cell production is driven by increased EPO levels.
    - Hypoxia-driven:
      - Chronic Lung Disease: COPD, pulmonary fibrosis.
      - High Altitude Living.
      - Sleep Apnea Syndrome: Obstructive sleep apnea (OSA).
      - Cyanotic Congenital Heart Disease.
      - High Oxygen Affinity Hemoglobinopathy: Rare genetic disorders.
      - Smoking: Due to elevated carboxyhemoglobin, leading to functional hypoxia.
    - Appropriate EPO Response (Physiological): Kidney disease leading to reduced renal oxygen delivery (e.g., renal artery stenosis).
    - Inappropriate EPO Response (Pathological):
      - EPO-secreting Tumors: Renal cell carcinoma (most common), hepatocellular carcinoma, cerebellar hemangioblastoma, uterine fibroids, adrenal adenoma, pheochromocytoma.
      - Renal Cysts/Hydronephrosis.
      - Exogenous EPO Administration/Androgens: Including performance-enhancing drugs (e.g., testosterone abuse).
- Relative Polycythemia (Pseudopolycythemia/Spurious Polycythemia): Normal red cell mass but reduced plasma volume, leading to an elevated Hct. Often associated with dehydration, diuretic use, or "stress polycythemia" (Gaisböck's syndrome).

Pathophysiology

Mechanism:
- Polycythemia Vera (PV): The hallmark of PV is an acquired mutation in the JAK2 gene, most commonly JAK2 V617F (present in ~95% of patients) or, less commonly, JAK2 exon 12 mutations (~3% of patients). These mutations lead to constitutive (uncontrolled) activation of the JAK2 tyrosine kinase, a key signaling molecule in the erythropoietin receptor pathway. This results in EPO-independent proliferation and differentiation of hematopoietic stem cells, primarily erythroid progenitors, but also megakaryocytes and granulocytes, leading to panmyelosis. This uncontrolled growth occurs despite low EPO levels.
- Secondary Polycythemia: Caused by an overproduction of EPO.
  - Hypoxia: Chronic tissue hypoxia (e.g., from lung disease, high altitude, sleep apnea, smoking) stimulates the kidneys to produce more EPO, which in turn stimulates red blood cell production in the bone marrow.
  - EPO-producing Tumors: Some tumors (e.g., renal cell carcinoma) autonomously produce EPO or EPO-like substances, leading to erythrocytosis independent of hypoxia.
- Relative Polycythemia: A decrease in plasma volume (e.g., due to dehydration, severe burns, diuretic use) concentrates the existing red blood cells, leading to an artificially elevated Hct without an actual increase in red cell mass.
Risk Factors:
- For PV: Advanced age (major risk factor), European ancestry (higher prevalence compared to other ethnic groups). Acquired somatic mutation of JAK2 is the causative factor. No strong hereditary predisposition, but familial clustering of MPNs is rarely observed.
- For Secondary Polycythemia:
  - Hypoxia: Smoking (leading to chronic carbon monoxide exposure and carboxyhemoglobinemia), chronic obstructive pulmonary disease (COPD), sleep apnea syndrome, obesity, residence at high altitude, cyanotic heart disease.
  - Renal Conditions: Renal artery stenosis, renal cysts.
  - Tumors: Renal cell carcinoma, hepatocellular carcinoma, cerebellar hemangioblastoma.
  - Exogenous Factors: Anabolic steroid use (e.g., testosterone replacement therapy), EPO doping.
Protective Factors:
- There are no known protective factors against primary polycythemia (PV).
- For secondary polycythemia, prevention and management of underlying conditions are key:
  - Smoking cessation.
  - Effective management of chronic lung diseases.
  - Diagnosis and treatment of sleep apnea (e.g., CPAP).
  - Weight management for obesity-hypoventilation syndrome.
  - Avoiding unnecessary exogenous testosterone or EPO.

Clinical Presentation

Signs and Symptoms

Cardinal Features: Symptoms related to hyperviscosity, thrombotic events, and myeloproliferation.
- Constitutional: Fatigue, headache, dizziness, weakness.
- Hyperviscosity-related: Blurred vision, tinnitus, vertigo, paresthesias.
- Pruritus: Often severe, generalized, and classically worsened by contact with water (aquagenic pruritus), affecting ~40-60% of PV patients.
- Erythromelalgia: Burning pain, warmth, and redness in the extremities (fingers and toes), relieved by aspirin.
- Thrombotic Events: Most serious complication. Deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, myocardial infarction, transient ischemic attacks (TIAs), splanchnic vein thrombosis (e.g., Budd-Chiari syndrome), portal vein thrombosis.
- Bleeding: Mucosal bleeding (epistaxis, gingival bleeding, GI bleeding), ecchymoses due to platelet dysfunction (acquired von Willebrand syndrome is rare but can occur with very high platelet counts >1,000,000/µL).
- Gout/Hyperuricemia: Due to increased cell turnover.
- Abdominal discomfort: Due to splenomegaly or hepatomegaly.
Early Signs: Often non-specific: fatigue, headache, dizziness, blurred vision, mild pruritus. Some patients are asymptomatic at diagnosis, found incidentally on routine CBC.
Advanced Signs:
- Progressive splenomegaly (leading to early satiety, abdominal pain).
- Symptoms of severe thrombosis or hemorrhage.
- Signs of myelofibrotic transformation: progressive anemia, worsening fatigue, night sweats, weight loss, progressive splenomegaly (with extramedullary hematopoiesis).
- Symptoms related to leukemic transformation (rare): fever, infections, severe anemia.
Atypical Presentations:
- Isolated splenomegaly without significant erythrocytosis early in the disease course.
- Unexplained thrombosis (especially splanchnic vein thrombosis) in a young patient.
- Only pruritus as the initial symptom.
- Asymptomatic erythrocytosis discovered incidentally.

Physical Examination

Inspection:
- Plethora: Ruddy cyanosis or generalized redness of the skin, especially facial plethora and conjunctival injection.
- Erythromelalgia: Red, warm, tender extremities.
- Livedo reticularis (mottled, reticulated vascular pattern on skin), particularly of the lower extremities.
- Signs of gout (tophi, inflamed joints).
- Signs of venous stasis or thrombosis (edema, warmth, tenderness).
Palpation:
- Splenomegaly: Palpable spleen is common in PV (present in ~75% of cases), ranging from mild to massive.
- Hepatomegaly: Less common than splenomegaly but can occur.
- Peripheral pulses (may be diminished if arterial thrombosis has occurred).
Special Tests: No specific tests on physical exam beyond general systemic examination to identify organomegaly or signs of thrombosis. Neurological examination for signs of stroke. Fundoscopic examination may reveal engorged retinal veins.

Diagnostic Approach

History Taking

Key Questions:
- Constitutional Symptoms: Fatigue, weakness, weight loss, night sweats.
- Hyperviscosity Symptoms: Headache, dizziness, blurred vision, tinnitus, paresthesias.
- Pruritus: Presence, severity, trigger (especially water exposure).
- Pain: Erythromelalgia, abdominal pain/early satiety (splenomegaly), joint pain (gout).
- Thrombotic/Bleeding Episodes: History of DVT, PE, stroke, MI, splanchnic thrombosis, unusual bleeding (epistaxis, GI bleed, easy bruising).
- Cardiopulmonary History: COPD, asthma, sleep apnea symptoms (snoring, daytime sleepiness, observed apneas), smoking history (pack-years).
- Exposure History: High altitude residence, carbon monoxide exposure.
- Medication History: Use of testosterone, EPO, diuretics.
- Family History: Polycythemia, blood disorders, MPNs.
- Other medical conditions: Kidney disease, liver disease.
Red Flags:
- Acute onset of neurological deficits (suggesting stroke).
- Acute chest pain, shortness of breath (MI, PE).
- Acute abdominal pain, jaundice, ascites (Budd-Chiari syndrome).
- Severe or uncontrolled bleeding.
- Rapidly worsening symptoms or signs of transformation (e.g., rapid increase in spleen size, new onset of profound fatigue, fever, weight loss).

Laboratory Tests

First-Line:
- Complete Blood Count (CBC) with Differential:
  - Hemoglobin (Hb) and Hematocrit (Hct): Elevated (often Hb >16.5 g/dL in men, >16.0 g/dL in women; Hct >49% in men, >48% in women, per WHO 2016 criteria).
  - Red Blood Cell (RBC) Count: Elevated.
  - White Blood Cell (WBC) Count: Often elevated (>10,000/µL) in PV.
  - Platelet Count: Often elevated (>400,000/µL) in PV.
  - Mean Corpuscular Volume (MCV): Often low in PV due to iron deficiency from increased red cell production or therapeutic phlebotomy.
- Erythropoietin (EPO) Level: Crucial for differentiation.
  - Low or Undetectable EPO: Highly suggestive of PV.
  - Normal or Elevated EPO: Suggests secondary polycythemia.
- Renal and Liver Function Tests: To assess organ function and rule out secondary causes.
Confirmatory (for PV):
- Molecular Testing for JAK2 Mutations:
  - JAK2 V617F mutation: Present in ~95% of PV patients. This is the primary diagnostic marker.
  - JAK2 exon 12 mutations: Found in ~3% of JAK2 V617F-negative PV patients.
- Bone Marrow Biopsy and Aspirate:
  - Indication: Not always required if JAK2 mutation is positive and other major criteria are met (Hb/Hct, splenomegaly, low EPO). However, it is often performed to assess for trilineage hyperplasia, reticulin fibrosis, and blast count, which are important for diagnosis confirmation and prognostic assessment, particularly in atypical cases, if JAK2 is negative, or to assess for myelofibrotic transformation.
  - Findings in PV: Hypercellularity for age, prominent panmyelosis (increased erythroid, myeloid, and megakaryocytic lineages), large, mature megakaryocytes with pleomorphic nuclei, and frequently increased reticulin fibrosis (especially later in the disease course).
- Other tests for secondary polycythemia:
  - Arterial Blood Gas (ABG): To assess for hypoxia (PaO2 <60-65 mmHg).
  - Carboxyhemoglobin level: To assess for carbon monoxide poisoning (e.g., in smokers).
  - Sleep Study (Polysomnography): To diagnose sleep apnea.
  - Imaging: Renal ultrasound, CT abdomen/pelvis, MRI brain (if specific tumor suspected).
Monitoring:
- CBC with Differential: Regularly (e.g., monthly initially, then every 3 months) to monitor Hct, WBC, platelet counts, and response to therapy.
- Iron Studies (Serum Ferritin, Iron, TIBC): To monitor iron status, as iron deficiency is common and can limit erythropoiesis.
- Lactate Dehydrogenase (LDH): May be elevated due to increased cell turnover.
- Uric Acid: Often elevated due to increased cell turnover, can monitor for hyperuricemia/gout.
- Symptom assessment: For pruritus, erythromelalgia, constitutional symptoms, and signs of thrombosis or bleeding.
- Physical exam: To monitor spleen size.

Imaging

Recommended:
- Chest X-ray (CXR): To evaluate for chronic lung disease as a cause of hypoxia.
- Abdominal Ultrasound: To assess for splenomegaly (characteristic of PV), hepatomegaly, and to screen for renal cysts or masses (potential EPO-secreting tumors).
- Echocardiogram with bubble study: If cardiac shunt is suspected (for hypoxia).
Advanced:
- CT Scan (Chest, Abdomen, Pelvis): If CXR is abnormal, to further evaluate lung disease. If renal mass is suspected (e.g., abnormal ultrasound, high EPO), for detailed tumor characterization. Used to evaluate thrombotic events (e.g., PE, splanchnic vein thrombosis).
- MRI (Brain/Spine): If cerebellar hemangioblastoma or other central nervous system tumor suspected (rare causes of EPO secretion).
- Sleep Study (Polysomnography): Confirms diagnosis of sleep apnea.

Management

Acute Management

Immediate (for symptomatic hyperviscosity or acute thrombosis):
- Therapeutic Phlebotomy: Rapid reduction of Hct to relieve symptoms of hyperviscosity (e.g., headache, dizziness, visual disturbances) or for acute thrombotic events. Aim for Hct <45% (men and women).
- Hydration: Intravenous fluids to reduce blood viscosity in severe cases.
Stabilization:
- Anticoagulation: For acute thrombotic events (e.g., DVT, PE, stroke, MI), according to standard guidelines.
- Analgesics: For pain related to erythromelalgia or thrombosis.
- Admission: Consider for severe symptomatic hyperviscosity or acute life-threatening complications.
Emergency:
- Emergency phlebotomy: For severe neurological symptoms due to hyperviscosity.
- Acute management of stroke, MI, PE: Standard protocols for these emergencies, including immediate therapeutic phlebotomy to reduce Hct.

Chronic Management

Pharmacological:
- Antiplatelet Therapy:
  - Low-dose Aspirin: 75-100 mg orally once daily. Recommended for almost all PV patients unless contraindicated (e.g., active bleeding, severe allergic reaction). Reduces the risk of thrombotic events.
- Cytoreductive Therapy: Indicated for high-risk PV patients (age >60 years, history of thrombosis, platelet count >1,500,000/µL, or significant leukocytosis) or those with severe symptoms not controlled by phlebotomy alone (e.g., severe pruritus, progressive splenomegaly).
  - Hydroxyurea (HU): First-line cytoreductive agent for high-risk PV.
    - Mechanism: Inhibits DNA synthesis.
    - Dose: Typically starting at 15-20 mg/kg/day or 500-1000 mg/day orally. Adjusted to maintain Hct <45%, and control WBC and platelet counts.
    - Monitoring: Weekly or bi-weekly CBC until stable, then monthly.
    - Side Effects: Myelosuppression (leukopenia, thrombocytopenia, anemia), mucocutaneous toxicity (leg ulcers, skin darkening, nail changes), gastrointestinal upset.
  - Pegylated Interferon Alpha (Peg-IFN-α):
    - Indication: Alternative first-line for younger patients, pregnant patients (after first trimester, under specialist guidance), or those intolerant/resistant to HU.
    - Dose: e.g., Pegasys 90-180 mcg subcutaneously weekly or Besremi (Ropeginterferon alfa-2b) starting at 100-250 mcg every 2 weeks or monthly.
    - Side Effects: Flu-like symptoms, fatigue, depression, autoimmune disorders, myelosuppression.
  - Ruxolitinib: (JAK1/2 inhibitor)
    - Indication: For patients who are intolerant of or whose disease is resistant to hydroxyurea, or for those with symptomatic splenomegaly or severe constitutional symptoms.
    - Dose: Starting at 10 mg orally twice daily.
    - Side Effects: Thrombocytopenia, anemia, infections (including herpes zoster).
  - Busulfan: Oral alkylating agent, used rarely in very elderly or frail patients not tolerating other agents.
- Symptomatic Management:
  - Antihistamines (e.g., cetirizine, diphenhydramine) for pruritus; consider SSRIs (e.g., paroxetine) for refractory aquagenic pruritus.
  - Allopurinol or Febuxostat: For hyperuricemia or gout.
  - Iron Supplementation: Contraindicated in PV unless there is documented iron deficiency that is severely symptomatic or refractory to other treatments, as it can stimulate erythropoiesis. Iron deficiency is a desired therapeutic consequence of phlebotomy.
- For Secondary Polycythemia:
  - Treat the underlying cause: Oxygen therapy for hypoxia, CPAP for sleep apnea, smoking cessation, surgical removal of EPO-secreting tumors, phlebotomy in selected cases (e.g., cyanotic heart disease with Hct >65% and symptoms).
Non-pharmacological:
- Therapeutic Phlebotomy: Cornerstone of PV management for all patients.
  - Goal: Maintain Hct below 45% in both men and women (based on evidence from the CYTO-PV trial showing reduced cardiovascular mortality with a strict Hct target).
  - Frequency: Initially weekly or bi-weekly (removing 450-500 mL of blood per session) until Hct goal is reached, then less frequently (e.g., every 1-3 months) for maintenance.
- Lifestyle Modifications:
  - Smoking cessation.
  - Regular exercise and weight management.
  - Good hydration.
  - Avoid high altitudes if they exacerbate symptoms.
- Nutritional Counseling: Balanced diet.
Monitoring:
- Regular CBC (every 1-3 months, or more frequently if on cytoreductive therapy).
- Clinical assessment for symptoms (pruritus, fatigue, new thrombotic/bleeding events).
- Physical exam for spleen size.
- Annual or biannual review of iron studies, LDH, uric acid.
- Monitoring for transformation to myelofibrosis or AML.

Treatment Algorithms (PV)

Risk Stratification for PV:
- Low-risk: Age <60 years AND no history of thrombosis.
- High-risk: Age ≥60 years OR history of thrombosis.
- Some guidelines consider extreme leukocytosis (>15 x 10^9/L) or extreme thrombocytosis (>1.5 x 10^12/L) as additional risk factors for thrombosis.
First-Line:
- All patients: Low-dose aspirin (75-100 mg daily) unless contraindicated.
- Low-risk PV: Therapeutic phlebotomy to maintain Hct <45%.
- High-risk PV: Therapeutic phlebotomy to maintain Hct <45% PLUS cytoreductive therapy (typically Hydroxyurea).
Second-Line:
- For Hydroxyurea intolerance or resistance (PV):
  - Pegylated Interferon Alpha (Peg-IFN-α): Preferred for younger patients, pregnant patients, or those desiring non-chemotherapeutic option.
  - Ruxolitinib: For patients with symptomatic splenomegaly, severe constitutional symptoms, or who are intolerant/resistant to hydroxyurea.
Refractory Cases:
- Failure to achieve Hct <45% with max tolerated HU.
- Uncontrolled myeloproliferation (persistent high WBC or platelets despite max tolerated HU).
- Persistent severe symptoms (pruritus, splenomegaly) despite HU.
- Consider Ruxolitinib.
- Consider clinical trials for novel agents.
- In very rare cases, allogeneic hematopoietic stem cell transplantation might be considered for young patients with advanced myelofibrotic transformation or high-risk features for leukemic transformation.

Complications

Common:
- Thrombosis: Most frequent and serious complication. Arterial (stroke, MI, TIA, peripheral arterial occlusion) and venous (DVT, PE, splanchnic vein thrombosis, Budd-Chiari syndrome).
- Bleeding: Often associated with very high platelet counts (platelet dysfunction) or rapid Hct reduction.
- Pruritus: Can be debilitating.
- Gout/Hyperuricemia: Due to increased cell turnover.
- Iron Deficiency: Common consequence of phlebotomy.
Serious:
- Myelofibrotic Transformation (Post-PV Myelofibrosis): Occurs in 10-20% of PV patients over 10-15 years. Characterized by progressive splenomegaly, worsening anemia, constitutional symptoms, and bone marrow fibrosis.
- Acute Myeloid Leukemia (AML) Transformation: Rare (2-5% risk over 10-15 years), but a devastating complication. Risk may be slightly increased with prior exposure to alkylating agents (e.g., Busulfan).
- Budd-Chiari Syndrome: Thrombosis of hepatic veins, leading to liver congestion.
- Stroke/Myocardial Infarction/Pulmonary Embolism: Major causes of morbidity and mortality.
Long-term:
- Progression of constitutional symptoms.
- Persistent need for phlebotomy or cytoreductive therapy with associated side effects.
- Increased risk of secondary malignancies (less clear evidence for non-hematologic malignancies).

Prognosis

Factors:
- Age: Older age at diagnosis is an adverse prognostic factor.
- History of thrombosis: Strongest independent risk factor for future thrombotic events and reduced survival.
- Leukocytosis: WBC count >15 x 10^9/L associated with higher risk of thrombosis and progression.
- JAK2 V617F allele burden: High allele burden may correlate with higher risk of progression to myelofibrosis, but its prognostic value for thrombosis is debated.
- Karyotype abnormalities: Presence of additional cytogenetic abnormalities at diagnosis or during disease course (e.g., del(20q), del(13q)) may indicate higher risk of progression.
- Response to therapy: Patients who achieve and maintain Hct <45% and control symptoms generally have better outcomes.
Survival:
- Polycythemia Vera: With modern management (phlebotomy and low-dose aspirin), median survival is significantly improved, often exceeding 15-20 years. Life expectancy can approach that of age- and sex-matched controls, particularly in younger, low-risk patients. However, the disease is chronic and incurable (except by allogeneic transplant in rare cases of transformation).
- Secondary Polycythemia: Prognosis is largely determined by the underlying cause. If the cause is treatable (e.g., sleep apnea, EPO-producing tumor), the prognosis can be excellent.
Quality of Life: Can be significantly impacted by symptoms like fatigue, pruritus, and by side effects of therapies (e.g., mucocutaneous issues with hydroxyurea, flu-like symptoms with interferon). Thrombotic events cause acute morbidity.

Prevention

Primary:
- For PV: No known primary prevention as it is an acquired genetic disorder.
- For Secondary Polycythemia:
  - Smoking cessation: Crucial to prevent hypoxia-induced polycythemia.
  - Management of sleep apnea: Adherence to CPAP therapy.
  - Responsible use of testosterone/EPO: Avoid supraphysiological doses or unmonitored use.
  - Early detection and treatment of underlying conditions: e.g., prompt diagnosis and treatment of renal cell carcinoma.
Secondary:
- For PV: Early diagnosis and consistent management (phlebotomy, aspirin, cytoreductive therapy) to prevent thrombotic events, which are the leading cause of morbidity and mortality. Regular monitoring for progression to myelofibrosis or AML.
- For Secondary Polycythemia: Timely identification and treatment of the underlying cause.
Tertiary:
- For PV: Adherence to long-term therapy, regular monitoring for complications (thrombosis, bleeding, transformation). Prompt treatment of complications.
- For all polycythemias: Education of patients about symptoms of complications and adherence to lifestyle modifications.

Special Populations

Pediatric:
- PV is extremely rare in children; when it occurs, it may have different genetic drivers and often presents with more aggressive features.
- Primary familial and congenital polycythemia (PFCP) forms are more common, often due to EPO receptor mutations.
- Secondary polycythemia in children is often due to cyanotic heart disease or chronic lung disease.
- Management is highly individualized, often involving phlebotomy and, for PV, pegylated interferon alpha is generally preferred over hydroxyurea due to long-term safety concerns.
Geriatric:
- Higher incidence of PV.
- Increased risk of thrombotic events.
- Higher prevalence of comorbidities and polypharmacy, requiring careful consideration of drug interactions and side effects (e.g., myelosuppression from hydroxyurea).
- Tolerance to phlebotomy may be reduced due to cardiovascular status.
- Management goals may shift towards symptom control and thrombosis prevention rather than aggressive disease modification.
Pregnancy:
- PV in pregnancy is rare but high-risk for both mother and fetus (increased risk of miscarriage, intrauterine growth restriction, preeclampsia, thrombosis).
- Hydroxyurea is contraindicated due to teratogenicity.
- Low-dose aspirin (75-100 mg daily) is recommended and generally considered safe.
- Pegylated interferon alpha is the preferred cytoreductive agent during pregnancy (especially after the first trimester).
- Therapeutic phlebotomy is safe and often necessary to maintain Hct <45%.
- Close monitoring by a multidisciplinary team (hematologist, obstetrician specializing in high-risk pregnancy).
Comorbidities:
- Cardiovascular Disease: Careful monitoring during phlebotomy (risk of hypotension, angina). Aspirin use requires balancing thrombotic and bleeding risks.
- Renal Impairment: Hydroxyurea dosage may need adjustment.
- Liver Disease: Can complicate assessment of EPO levels; increased risk of bleeding.
- Gout: Requires concurrent management with allopurinol/febuxostat.

Clinical Pearls

Diagnostic:
- Always rule out secondary causes (hypoxia, EPO-secreting tumors, testosterone use) before diagnosing PV. A normal or high EPO level strongly argues against PV.
- A low MCV in an erythrocytotic patient is a strong clue for PV, due to the rapid iron utilization from high red cell turnover and therapeutic phlebotomy.
- The JAK2 V617F mutation is the cornerstone of PV diagnosis. If negative, check for exon 12 mutations if PV is still suspected.
- Hct of 45% is the key target in PV management, not just Hb.
- Remember aquagenic pruritus – a highly specific symptom for MPNs, especially PV.
Treatment:
- Therapeutic phlebotomy is the fastest way to reduce Hct and relieve hyperviscosity symptoms.
- Low-dose aspirin is mandatory for almost all PV patients to prevent thrombosis, unless there are severe contraindications.
- Avoid iron supplementation in PV, as it can stimulate erythropoiesis and counteract phlebotomy efforts.
- Hydroxyurea is the workhorse for high-risk PV. Monitor for myelosuppression and mucocutaneous side effects.
- Consider Peg-IFN-α for younger patients or those with intolerance/resistance to HU, especially those planning pregnancy.
- Ruxolitinib is for refractory disease or symptomatic splenomegaly/constitutional symptoms.
Pitfalls:
- Misdiagnosing relative polycythemia as absolute polycythemia, leading to unnecessary investigations or treatments.
- Failing to achieve the Hct target of <45%, which is crucial for reducing thrombotic risk.
- Overlooking the rare JAK2 exon 12 mutation in V617F-negative patients strongly suspected of having PV.
- Incorrectly prescribing iron supplements to PV patients with mild iron deficiency, leading to increased Hct.
- Ignoring patient symptoms (e.g., pruritus, fatigue) that significantly impact quality of life, even if blood counts are controlled.

Recent Updates

Guidelines:
- WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues (5th Edition, 2022): Updated diagnostic criteria for MPNs, including PV, emphasizing the role of JAK2 mutations and bone marrow morphology.
- European LeukemiaNet (ELN) and American Society of Hematology (ASH) guidelines: Continually updated recommendations for diagnosis and management of PV, reinforcing the Hct target of <45% and risk-adapted therapeutic approaches.
Evidence:
- CYTO-PV Study (2013): Landmark study demonstrating that maintaining Hct <45% (compared to 45-50%) significantly reduced the rate of cardiovascular death and major thrombotic events in PV patients receiving phlebotomy-based treatment.
- RESPONSE/RESPONSE-2 Trials: Established Ruxolitinib's efficacy in patients with PV resistant to or intolerant of hydroxyurea, showing significant improvement in Hct control, splenomegaly, and symptoms.
- PROUD-PV and CONTINUATION-PV studies: Demonstrated comparable efficacy and safety of ropeginterferon alfa-2b (Besremi) to hydroxyurea, establishing it as a valid first-line option.
Controversies:
- Role of bone marrow biopsy in all JAK2-positive PV cases: While not strictly required by all guidelines if major criteria are met, it is often performed for complete diagnostic staging and assessment of fibrosis.
- Optimal management of younger, low-risk PV patients: While phlebotomy and aspirin are standard, some advocate for earlier cytoreductive therapy (e.g., Peg-IFN-α) to potentially alter disease progression, though long-term data are still evolving.
- Impact of specific JAK2 allele burden on prognosis and treatment decisions.

Key References

Guidelines:
- World Health Organization (WHO): WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 5th Edition (2022). Provides the definitive diagnostic criteria for polycythemia vera and other myeloproliferative neoplasms.
- European LeukemiaNet (ELN): Published recommendations for diagnosis and management of polycythemia vera. For example, Barbui et al. European LeukemiaNet 2013 recommendations for the diagnosis and management of polycythemia vera with a focus on rare complications. Leukemia. 2015 May;29(5):1018-24.
- American Society of Hematology (ASH): Guidelines for the management of polycythemia vera. Tefferi et al. Polycythemia Vera: ASH Clinical Practice Guidelines for the Management of Polycythemia Vera. Blood Adv. 2020 Jan 28;4(2):339-354.
- National Comprehensive Cancer Network (NCCN): Clinical Practice Guidelines in Oncology – Myeloproliferative Neoplasms.
Studies:
- CYTO-PV Study: Marchioli R, et al.; CYTO-PV Collaborative Group. Cardiovascular events in polycythemia vera: a randomized trial of hydroxyurea vs phlebotomy in patients with a hematocrit target of less than 45%. N Engl J Med. 2013 Jun 27;368(26):2555-64.
- ECLAP Study: Landolfi R, et al.; European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004 May 6;350(17):114-24.
- RESPONSE Trial: Vannucchi AM, et al.; RESPONSE Trial. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015 Mar 5;372(5):426-35.
Reviews:
- Spivak JL, et al. Polycythemia Vera. Blood. 2014 Mar 20;123(12):1791-801.
- Vannucchi AM, et al. Polycythemia Vera: An Update on Molecular Pathogenesis, Diagnosis, and Therapy. J Clin Oncol. 2015 Aug 10;33(23):2566-74.